Drug intelligence / Profile preview

OPG-specific siRNA

Development stage
Unknown
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Ophthalmic, Intravitreal, Vaginal, Intratumoral, Intraperitoneal
01

Overview

OPG-specific siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of osteoprotegerin (OPG, also known as TNFRSF11B). OPG is a decoy receptor for receptor activator of nuclear factor-κB ligand (RANKL) and plays a critical role in bone remodeling by inhibiting osteoclastogenesis. In oncology research, OPG-specific siRNA is utilized to investigate the role of endogenous OPG in tumor progression and metastasis, particularly in breast cancer cells where OPG expression is regulated by NF-κB. Knockdown of OPG using this siRNA has been shown to significantly reduce metastasis in in vivo models, suggesting that targeting OPG could be a potential therapeutic strategy for certain breast cancer subtypes.

Other names
OPG siRNAosteoprotegerin siRNAosteoprotegerin-specific siRNA
02

Targets

OPG (Osteoprotegerin)

Beyond the preview

Go deeper on OPG-specific siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPG-specific siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call